Data gathered: January 16
Alternative Data for Mersana Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 7 | Sign up | Sign up | Sign up |
| Sentiment | 90 | Sign up | Sign up | Sign up |
| Webpage traffic | 5,000 | Sign up | Sign up | Sign up |
| Employee Rating | 84 | Sign up | Sign up | Sign up |
| Google Trends | 16 | Sign up | Sign up | Sign up |
| Patents | 32 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 445 | Sign up | Sign up | Sign up |
| Reddit Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 24 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,658 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,492 | Sign up | Sign up | Sign up |
| Twitter Mentions | 17 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 58 | Sign up | Sign up | Sign up |
| Linkedin Employees | 159 | Sign up | Sign up | Sign up |
About Mersana Therapeutics
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs.
| Price | $0.61 |
| Target Price | Sign up |
| Volume | 13,190,000 |
| Market Cap | $78M |
| Year Range | $0.61 - $2.77 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Mersana Therapeutics SVP sells $2,450 in stockJanuary 15 - Investing.com |
 |
Barclays PLC Has $934,000 Stock Position in Mersana Therapeutics, Inc. (NASDAQ:MRSN)January 15 - ETF Daily News |
|
Mersana Therapeutics Announces Positive Initial Clinical Data and FDA Fast Track Designation for Emiltatug Ledadotin (XMT-1660)January 13 - ETF Daily News |
 |
Mersana Therapeutics’ (MRSN) Outperform Rating Reiterated at WedbushJanuary 12 - ETF Daily News |
 |
Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?January 10 - Biztoc.com |
Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)January 10 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 13M | 9.9M | 2.7M | -12M | 0 | -0.090 |
| Q2 '24 | 2.3M | 11M | -8.2M | -24M | -24M | -0.200 |
| Q1 '24 | 8.2M | 12M | -3.3M | -19M | -21M | -0.160 |
| Q4 '23 | 9.7M | 11M | -1.2M | -20M | -20M | -0.160 |
| Q3 '23 | 6.7M | 21M | -14M | -42M | -42M | -0.270 |
Insider Transactions View All
| Bala Mohan filed to sell 60,228 shares at $0.7. January 15 '25 |
| Carvajal Alejandra filed to sell 69,344 shares at $0.7. January 15 '25 |
| DeSchuytner Brian filed to sell 105,111 shares at $0.7. January 15 '25 |
| Lowinger Timothy B filed to sell 242,932 shares at $0.7. January 15 '25 |
| Mandelia Ashish filed to sell 49,396 shares at $0.7. January 15 '25 |
Similar companies
Read more about Mersana Therapeutics (MRSN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Mersana Therapeutics?
The Market Cap of Mersana Therapeutics is $78M.
What is the current stock price of Mersana Therapeutics?
Currently, the price of one share of Mersana Therapeutics stock is $0.61.
How can I analyze the MRSN stock price chart for investment decisions?
The MRSN stock price chart above provides a comprehensive visual representation of Mersana Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Mersana Therapeutics shares. Our platform offers an up-to-date MRSN stock price chart, along with technical data analysis and alternative data insights.
Does MRSN offer dividends to its shareholders?
As of our latest update, Mersana Therapeutics (MRSN) does not offer dividends to its shareholders. Investors interested in Mersana Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Mersana Therapeutics?
Some of the similar stocks of Mersana Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.